Thank you for your interest in participating in the Phase III Patidegib 2% topical gel clinical trial for the reduction of disease burden of basal cell carcinomas in Gorlin Syndrome sponsored by PellePharm. The participating sites in the US are listed below and is divided into three categories based upon their current status of enrollment.
Tier 1: Sites that are fully activated and can actively screen on-site and dose patients.
Tier 2: Sites that can pre-screen and where activation in eminent.
Tier 3: Sites that have committed to participating in the trial but have not completed activation yet.
Please note: If there is no site close to you or a site has not opened yet, but you are interested in participating now, PellePharm is reimbursing patients for travel to remote sites. However, you must be willing to commit to a monthly trip to that site for one year and you cannot switch to another site mid-study. As site status changes, this list will be updated accordingly, so please stay in touch with our office. If all goes as planned, all sites should move up to the tier 1 status within the next few months.
|Tier 1 – Sites that are fully activated and can actively screen on-site and dose patients.
||Study Coordinator Contact Info
||Mayo Clinic-Mayo Clinic Hospital-Phoenix
||Dr. Aleksandar Sekulic
||480.301.4714 or JeanLouis.Narcelle@mayo.edu
||Redwood City (Stanford Univ.)
||Dr. Anne Chang
||650.498.5185 or firstname.lastname@example.org
||Dr. Michelle Aszterbaum
||949.644.8556 or email@example.com
||Dr. Sarah Arron
||415.353.9684 or Christine.firstname.lastname@example.org
||New Haven (Yale)
||Dr. Sean Christensen
||203.785.5505 or email@example.com
||Dr. James Solomon
||386.523.0768 or Sandra.firstname.lastname@example.org
||Dr. Jennifer Tang
||305.243.8485 or email@example.com
||Dr. Diana Bolotin
||K. Yazmin Reyna-Blanco
||773.702.7696 or firstname.lastname@example.org
||Dr. William Hanke
||317.660.4862 or email@example.com
||Ann Arbor (UM)
||Dr. Andrzej Dulgosz
||734.936.4070 or firstname.lastname@example.org
||Minneapolis (Univ. of Minnesota)
||Dr. Ian Maher
||612.624.5721 or email@example.com
||St. Louis (St. Louis Univ Hosp)
||Dr. Patricia Missall
||314.256.3436 or firstname.lastname@example.org
||Dr. Meenal Kheterpal
||919.684.1830 or email@example.com
||Dr. David Bickers
||212.305.8444 or firstname.lastname@example.org
||Dr. Anna Bar
||503.494.4700 or email@example.com
||Hummelston (Penn State Hershey)
||Dr. Elizbeth Billingsley
||717.531.4439 or firstname.lastname@example.org
||Dr. Emily Chu
||Salt Lake City (Uni of Utah Midvalley)
||Dr. Keith Duffy
||801.213.0373 or Rachel.email@example.com
|Tier 2 – Sites that can pre-screen and where activation in eminent.
|Tier 3: Sites committed to participating in the trial but have not completed activation yet.
You can also learn more about this clinical trial by visiting www.gorlinstudy.com.